| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| 100mg | |||
| 250mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
The primary target of desacetylcefotaxime is the bacterial cell wall, specifically the penicillin-binding proteins (PBPs) that are essential for bacterial cell wall synthesis. As a cephalosporin antibiotic, desacetylcefotaxime binds to PBPs and inhibits the transpeptidase enzymes that cross-link peptidoglycan strands, a critical step in bacterial cell wall formation. This inhibition leads to the weakening of the bacterial cell wall, osmotic instability, and ultimately bacterial cell lysis and death. The compound's broad-spectrum activity is due to its ability to bind to multiple PBPs in both Gram-positive and Gram-negative bacteria. Its activity against Gram-negative bacteria is enhanced by its ability to penetrate the outer membrane.
|
|---|---|
| ln Vitro |
In vitro, desacetylcefotaxime demonstrates antibacterial activity against a variety of aerobic and anaerobic bacteria, with effects similar to those of the parent compound cefotaxime. It is particularly effective against Gram-negative bacteria. The compound's antibacterial activity is typically assessed using standard broth microdilution assays to determine minimum inhibitory concentrations (MICs) against a panel of bacterial strains. Desacetylcefotaxime retains significant antibacterial activity despite being a metabolite, contributing to the overall therapeutic efficacy of cefotaxime. Its broad-spectrum activity makes it useful for treating a wide range of bacterial infections. The compound's in vitro activity against resistant strains may vary depending on the resistance mechanisms present.
|
| ln Vivo |
In vivo, desacetylcefotaxime is the primary active metabolite of cefotaxime, formed in the liver through deacetylation. It contributes to the overall antibacterial activity of cefotaxime therapy. The compound is distributed to various tissues and body fluids, including the cerebrospinal fluid, where it is effective against central nervous system infections. Its antibacterial activity is similar to that of the parent compound against a variety of aerobic and anaerobic bacteria. Desacetylcefotaxime is excreted primarily in the urine. The compound's in vivo efficacy has been demonstrated in clinical studies of cefotaxime, where the metabolite contributes to the overall antibacterial effect.
|
| Enzyme Assay |
In vitro antibacterial susceptibility testing for desacetylcefotaxime follows standard protocols established for cephalosporin antibiotics. The broth microdilution method is commonly used, where bacterial cultures are grown in 96-well plates containing serial dilutions of the antibiotic. After incubation at 37°C for 16-24 hours, the minimum inhibitory concentration (MIC) is determined as the lowest concentration of the antibiotic that inhibits visible bacterial growth. The compound's activity can also be assessed using disk diffusion (Kirby-Bauer) methods, where antibiotic-impregnated disks are placed on agar plates inoculated with bacteria, and the zone of inhibition is measured. These assays are standard for characterizing the antibacterial activity of desacetylcefotaxime and other cephalosporins.
|
| Cell Assay |
In vitro cell-based assays for desacetylcefotaxime are not typically performed, as the compound's mechanism of action is direct antibacterial activity rather than effects on eukaryotic cells. However, cytotoxicity assays using mammalian cell lines can be conducted to assess the compound's safety profile and potential for off-target effects. These assays involve treating cells with varying concentrations of desacetylcefotaxime and measuring cell viability using standard assays such as MTT or LDH release. Additionally, the compound's effects on bacterial adhesion, biofilm formation, or other virulence factors can be assessed in cell-based models of infection. These assays provide additional data on the compound's biological activity beyond its antibacterial effects.
|
| Animal Protocol |
In vivo animal studies for desacetylcefotaxime are typically conducted in the context of cefotaxime pharmacology, as desacetylcefotaxime is a metabolite of the parent drug. Efficacy studies involve infecting animals (typically mice or rats) with a bacterial pathogen and then treating them with cefotaxime, with subsequent measurement of desacetylcefotaxime levels and antibacterial activity. Pharmacokinetic studies assess the formation, distribution, metabolism, and excretion of desacetylcefotaxime following cefotaxime administration. These studies are essential for understanding the contribution of the metabolite to the overall therapeutic efficacy of cefotaxime.
|
| ADME/Pharmacokinetics |
Desacetylcefotaxime has a molecular weight of approximately 397.43 g/mol. As a cephalosporin antibiotic, it is typically administered parenterally when used as part of cefotaxime therapy. The compound is formed in the liver through deacetylation of cefotaxime and is distributed to various tissues and body fluids. It is primarily excreted in urine. Its half-life is similar to or slightly longer than that of cefotaxime, and it accumulates in patients with renal impairment. The compound's antibacterial activity is similar to that of the parent compound against a variety of bacteria. Its pharmacokinetic properties are well-characterized in the clinical pharmacology literature.
|
| Toxicity/Toxicokinetics |
Desacetylcefotaxime is generally well-tolerated, with a safety profile similar to other cephalosporin antibiotics. Common side effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea. Hypersensitivity reactions, including rash and anaphylaxis, can occur, particularly in patients with a history of penicillin allergy. The compound can cause injection site reactions when administered parenterally. As with other cephalosporins, desacetylcefotaxime should be used with caution in patients with renal impairment, as dose adjustment may be necessary. The compound is classified as a pregnancy category B drug.
|
| References |
|
| Additional Infomation |
Desacetylcefotaxime (CAS# 66340-28-1) is a semi-synthetic cephalosporin antibiotic and the primary in vivo metabolite of cefotaxime. It retains significant antibacterial activity, particularly against Gram-negative bacteria. The compound's antibacterial effects are similar to those of cefotaxime against a variety of aerobic and anaerobic bacteria. It is formed in the liver through deacetylation. Desacetylcefotaxime has applications in medical, environmental, and industrial research. It has not received FDA approval as a standalone therapeutic agent.
|
| Molecular Formula |
C14H15N5O6S2
|
|---|---|
| Molecular Weight |
413.43
|
| Exact Mass |
413.046
|
| Elemental Analysis |
C, 40.67; H, 3.66; N, 16.94; O, 23.22; S, 15.51
|
| CAS # |
66340-28-1
|
| Related CAS # |
66340-28-1
|
| PubChem CID |
9576239
|
| Appearance |
White to off-white solid powder
|
| LogP |
-1.9
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
27
|
| Complexity |
729
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
CON=C(C1=CSC(=N1)N)C(=O)NC2C3N(C2=O)C(=C(CS3)CO)C(=O)O
|
| InChi Key |
FHYWAOQGXIZAAF-GHXIOONMSA-N
|
| InChi Code |
InChI=1S/C14H15N5O6S2/c1-25-18-7(6-4-27-14(15)16-6)10(21)17-8-11(22)19-9(13(23)24)5(2-20)3-26-12(8)19/h4,8,12,20H,2-3H2,1H3,(H2,15,16)(H,17,21)(H,23,24)/b18-7-/t8-,12-/m1/s1
|
| Chemical Name |
5-Thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-(((2-amino-4-thiazolyl)(methoxyimino)acetyl)amino)-3-(hydroxymethyl)-8-oxo-, (6R-(6alpha,7beta(Z)))-
|
| Synonyms |
Desacetylcefotaxime; Deacetylcefotaxime; 3-Desacetyl cefotaxime
|
| HS Tariff Code |
2934.99.03.00
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~250 mg/mL (~604.70 mM)
DMSO : ~250 mg/mL (~604.70 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4188 mL | 12.0939 mL | 24.1879 mL | |
| 5 mM | 0.4838 mL | 2.4188 mL | 4.8376 mL | |
| 10 mM | 0.2419 mL | 1.2094 mL | 2.4188 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA